- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01964547
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Prague, Czechia, 128 08
- MS Centre, Charles University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (ALL to be fulfilled):
- Patient is willing and able to give informed consent for participation in the study.
- Patient is aged 18 years or above.
- Diagnosed with any disease sub-type of multiple sclerosis.
- Diagnosed with symptomatic spasticity due to multiple sclerosis.
- Patient has at least moderate spasticity in the opinion of the investigator.
Patient fulfils at least one of the two criteria below. Subject must be either:
- Currently established on a regular dose of anti-spasticity therapy, or
- Previously tried and failed anti-spasticity therapy.
- Stable medication regimen for at least four weeks prior to study entry, for all medications which may have an effect on spasticity and/or cognition.
- If the patient is taking disease modifying medication this must be at a stable dose for three months prior to the initial visit.
- Willing and able to comply with all study requirements.
- Willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable.
- Willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.
Exclusion Criteria (if ANY apply):
- Any history or immediate family of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- Any concomitant disease or disorder (such as poorly controlled epilepsy or seizures) that may influence the patient's level of cognition or mood.
- Currently using or has used cannabis or cannabinoid-based medications within 30 days of study entry and unwilling to abstain for the duration of the study.
- Any known or suspected history of a diagnosed dependence disorder, current heavy alcohol consumption (more than 60g of pure alcohol per day for men, and more than 40g of pure alcohol per day for women), current use of an illicit drug or current non-prescribed use of any prescription drug.
- Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products.
- Female patients of child bearing potential and male subjects whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter.
- Female patient who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
- Patients who have received an investigational medicinal product within the 12 weeks prior to the initial visit.
- Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study may influence the result of the study, or the patient's ability to participate in the study.
- Following a physical examination, the patient has any abnormalities that, in the opinion of the investigator would prevent the patient from safe participation in the study.
- Previously randomised to this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sativex
Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg. Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability. |
Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
Other Names:
|
Placebo Comparator: Placebo
Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day.
There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
|
Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to the End of Treatment in Paced Auditory Serial Addition Test (PASAT) Total Score.
Time Frame: 0-48 weeks
|
The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability.
Stimulus presentation rates were adapted for use with multiple sclerosis patients.
The PASAT is presented on audio compact disk to control the rate of stimulus presentation.
Single digits are presented either every 3 seconds (PASAT 1) or every 2 seconds (PASAT 2), and the patient must add each new digit to the one immediately prior to it.
The test score is the sum of the total number of correct sums given (out of 60 possible) in each trial.
An increase in score indicates an improvement in condition.
|
0-48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to the End of Treatment in Beck Depression Inventory-II (BDI-II) Total Score.
Time Frame: 0-48 weeks
|
The BDI-II is a multiple choice self-reported inventory that is one of the most widely used instruments for measuring the severity of depression.
There are 21 questions or items, each having four possible responses.
Each response is assigned a score ranging from zero to three, indicating the severity of the symptom.
Items 1 to 13 assess symptoms that are psychological in nature, while items 14 to 21 assess symptoms that are more physical.
The sum of all BDI-II item scores indicates the severity of depression.
For patients eligible for this study, a score of 21 or over represents depression.
The BDI-II can distinguish between different subtypes of depressive disorders, such as major depression and dysthymia.
A reduction in score indicates an improvement in condition.
|
0-48 weeks
|
Subject Global Impression of Change (SGIC) in the Severity of Their Spasticity at the End of Treatment.
Time Frame: 0-48 weeks
|
Patients were asked the following question, to be rated on a seven-point scale: "Please assess the change in your spasticity since immediately before receiving the first dose of study treatment (Visit 1) using the scale below". The markers were: 'Very much worse', 'Much worse', 'Minimally worse', 'No change', 'Minimally better', 'Much better' or 'Very much better'. The number of patients for each of the markers is presented at the final study visit. |
0-48 weeks
|
Caregiver's Global Impression of Change (CGIC) in the Severity of the Patient's Spasticity at the End of Treatment.
Time Frame: 0-48 weeks
|
Caregivers were asked the following question to be rated on a seven-point scale: "How has the subject's spasticity changed since Visit 1?" The markers were: Very much worse, Much worse, Minimally worse, No change, Minimally better, Much better, Very much better. The number of patients for each of the markers is presented at the final study visit. |
0-48 weeks
|
Physician's Global Impression of Change (PGIC) in the Severity of the Patient's Spasticity at the End of Treatment.
Time Frame: 0-48 weeks
|
Physicians were asked the following question to be rated on a seven-point scale: "How has the subject's spasticity changed since Visit 1?" The markers were: Very much worse, Much worse, Minimally worse, No change, Minimally better, Much better, Very much better. The number of patients for each of the markers is presented at the final study visit. |
0-48 weeks
|
Change From Baseline to End of Treatment in Modified Ashworth Scale Total Score.
Time Frame: 0-48 weeks
|
All 20 muscle groups were assessed for spasticity (using a 0-5 scale): 0= 'no increase in muscle tone' to 5= 'affected part(s) rigid in flexion or extension'.
The score for all 20 muscle groups were added to give a total score out of 100.
A decrease in score indicates an improvement in condition.
|
0-48 weeks
|
Change From Baseline to End of Treatment in Number of Visits to a Healthcare Professional.
Time Frame: 0-48 weeks
|
At baseline, patients were asked how many times they had visited a healthcare professional in the previous 12 weeks.
At subsequent visits, patients were asked how many times they had visited a healthcare professional since their last study visit.
The change from baseline to the end of treatment is presented.
A decrease in number indicates an improvement in condition.
|
0-48 weeks
|
The Number of Patients With a Treatment-emergent Flag Using the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Course of the Study.
Time Frame: 0-48 weeks
|
Patients were scored at each clinic visit for the following outcomes using the C-SSRS: suicidal ideation, suicidal behaviour, suicidality (including complete suicidality).
Possible flags were as follows: "Wish to be Dead", "Non-specific Active Suicidal Thoughts", "Active Suicidal Ideation Without Intent", "Active Suicidal Ideation With Intent, No Plan", "Active Suicidal Ideation With Intent and Plan".
The number of patients with a treatment-emergent flag is presented.
|
0-48 weeks
|
Change From Baseline to End of Treatment in Timed 10-meter Walk Times.
Time Frame: 0-48 weeks
|
Only those patients for whom it was appropriate (i.e.
ambulatory patients) were timed for how long it took to walk 10 metres.
If a patient started the 10-meter walk but was unable to complete it, an estimated time for completion was calculated based on the available data.
A negative difference from baseline indicates an improvement in condition.
|
0-48 weeks
|
Incidence of Adverse Events as a Measure of Patient Safety.
Time Frame: 0-50 weeks
|
The number of subjects who experienced an adverse event during the course of the study is presented.
|
0-50 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bosnjak Kuharic D, Markovic D, Brkovic T, Jeric Kegalj M, Rubic Z, Vuica Vukasovic A, Jeroncic A, Puljak L. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2021 Sep 17;9(9):CD012820. doi: 10.1002/14651858.CD012820.pub2.
- Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark. Mult Scler. 2013 Oct;19(11 Suppl):8-597. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Multiple Sclerosis
- Sclerosis
- Muscle Spasticity
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Nabiximols
Other Study ID Numbers
- GWMS1137
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Sativex
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity Disorder (ADHD)United Kingdom
-
AbbottRecruiting
-
Mary LynchCompleted
-
S. Andrea HospitalUniversity of Roma La SapienzaUnknown
-
Jazz PharmaceuticalsQuintiles, Inc.CompletedPain | Cancer | Palliative CareSpain, United Kingdom, United States, Canada, Poland, India, France, Czech Republic, Belgium, Romania, Chile, Finland, Germany, Italy, Mexico, South Africa
-
Jazz PharmaceuticalsCompleted
-
National Institute on Drug Abuse (NIDA)CompletedPharmacokinetics | Cannabis | Dependence | Cannabis Abuse | fMRIUnited States
-
Almirall, S.A.CompletedMultiple SclerosisItaly
-
Michael, Levy M.D.,Ph.D.Jazz PharmaceuticalsNot yet recruitingSpasticity, Muscle | NMO Spectrum DisorderUnited States
-
One World Cannabis Ltd.Completed